Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Keros Therapeutics, Inc.

NASDAQ: KROS · Life Sciences · 6 alerts · CIK 1664710

Share price
$10.03Close, Nov 16
Market cap
$197M
Shares outstanding
19.62MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Keros Therapeutics, Inc. filings on SEC EDGAR ↗

4:09 PM ET 8-K
Stock Buyback

Keros Therapeutics Announces $5M Stock Buyback

Keros Therapeutics announced that its Board of Directors approved a new $5 million share repurchase program for its common stock. The buyback authorization follows the company's receipt of a $20 million development milestone payment from Takeda Pharmaceuticals related to the clinical trial dosing of elritercept. Keros expects its current cash reserves, including this milestone, to fund operations into 2029.

Value
$5M
4:16 PM ET 8-K
Investor Presentation

Keros Therapeutics Investor Presentation

Keros Therapeutics updated its corporate presentation for use in meetings with investors and analysts. The presentation highlights the company's clinical pipeline, including rinvatercept (KER-065) for Duchenne muscular dystrophy and ALS, and elritercept for myelodysplastic syndromes.

4:04 PM ET 10-Q
Financial Results

Keros Therapeutics Q3 2026 Results: Turns Profitable, Net Income $14.2M

Keros Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for hematological and musculoskeletal disorders. The filing highlights ongoing Phase 2 trials for rinvatercept (KER-065) and elritercept (KER-050), the latter of which is being developed in collaboration with Takeda and Hansoh.

Key figure
Net income $14.2M
4:03 PM ET 8-K
Financial Results

Keros Therapeutics Financial Results

Keros Therapeutics reported third quarter 2026 financial results, highlighted by a net income of $14.2 million compared to a net loss in the prior year, primarily due to revenue recognition from its license agreement with Takeda. The company also announced the first patient dosed in its Phase 2 trial of rinvatercept for DMD and expects its $259.5 million cash balance to fund operations into the second half of 2028.

“We are excited to continue advancing our pipeline across both clinical and nonclinical development, building on our understanding of TGF-β biology to develop potential new treatments for patients. We remain focused on disciplined execution of our strategic priorities as we work to advance our programs and build on the potential of our pipeline.”

Jasbir S. Seehra, Ph.D., President and Chief Executive Officer
8:01 AM ET 8-K
Licensing Deal

Keros Therapeutics Licensing Deal with Takeda Pharmaceuticals U.S.A., Inc. Worth $20M

Keros Therapeutics announced it will receive a $20 million development milestone payment from its partner Takeda following the dosing of the first patient in the Phase 3 ELRiSE MF clinical trial for elritercept. The payment is part of a global license agreement that includes potential milestones exceeding $1.1 billion. Keros intends to distribute 25% of the net cash proceeds from this milestone to its stockholders.

Value
$20M
Counterparty
Takeda Pharmaceuticals U.S.A., Inc.
8:02 AM ET 8-K
Clinical Trial Data

Keros Therapeutics Clinical Trial Data

Keros Therapeutics announced the dosing of the first patient in its Phase 2 clinical trial evaluating rinvatercept for the treatment of Duchenne muscular dystrophy (DMD). The open-label, multi-cohort trial will assess safety, tolerability, and functional improvements in ambulatory and non-ambulatory patients, with initial data expected in the first half of 2027.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.